Track LENZ Therapeutics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

LENZ Therapeutics, Inc. LENZ · Stock Open LENZ Therapeutics, Inc. in new tab

3.29 USD
P/E
45.73
EPS
-4.53
P/B
0.66
ROE
-72.69
Beta
1.81
Target Price
14.83 USD
Loading chart...
Key Metrics
Earnings dateMarch 23, 2027
P/E45.73
EPS-4.53
Book Value6.11
Price to Book0.66
Debt/Equity0.24
% Insiders2.648%
Growth
Revenue Growth-0.73%
Estimates
Forward P/E-3.00
Forward EPS-1.35
Target Mean Price14.83

DCF valuation

Model fair value for LENZ Therapeutics, Inc. (LENZ)
Result
Sign in to run the valuation for LENZ.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
6 analysts · consensus Buy · mean target 14.83 USD (low 4.00, high 45.00) · as of 11 Nov 2026
Low 4.00
Mean 14.83
High 45.00
Price 3.29
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

LENZ Therapeutics, Inc. Logo LENZ Therapeutics, Inc. Analysis (LENZ)

Healthcare Official Website Stock

Is LENZ Therapeutics, Inc. a good investment? LENZ Therapeutics, Inc. (LENZ) is currently trading at 3.29 USD. Market analysts have a consensus price target of 14.83 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 45.73. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: LENZ Therapeutics, Inc. is expected to release its next earnings report on March 23, 2027. The market consensus estimate for Forward EPS is -1.35.

Investor FAQ

Does LENZ Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is LENZ Therapeutics, Inc.?

LENZ Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 23, 2027. The company currently has a trailing EPS of -4.53.

Company Profile

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.

Exchange Ticker
NASDAQ LENZ
Trades
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
▸2024
16.48 USD
March 22, 2024 1.0300
March 22, 2024 7.2100
March 15, 2024 1.0300
March 15, 2024 7.2100
Stock Splits
Split Date Split Ratio to 1
March 22, 2024 1:7
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion